MAIA - AMEX
MAIA Biotechnology, Inc.
$1.49
+4.2%MAIA Biotechnology, Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer, primarily non-small cell lung cancer. Its lead asset, THIO, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The company was founded in 2018 and is headquartered in Chicago, Illinois.
At a Glance
Live SnapshotMAIA Biotechnology, Inc. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Strong cash conversion. Most reported earnings translate into actual cash flow, suggesting solid fundamentals.
FCF Growth Trend
Significant FCF decline raises concerns. Urgent review needed of operational performance and capital allocation.
Working Capital Impact
Working capital inflow boosted cash flow. Efficient management of receivables, inventory, and payables contributing positively.
MAIA Biotechnology, Inc. Cash Flow Statement
MAIA • AMEX
| MAIA Biotechnology, Inc. Cash Flow Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|---|---|
OPERATING ACTIVITIES | |||||||
-22.4M | -23.3M | -19.8M | -15.8M | -12.6M | -7M | -6.5M | |
2.6M | 1.9M | 3.1M | 2.3M | 2.7M | 3.9M | 0.0 | |
-579.4K | 6.9M | 526.5K | 1M | 4.6M | -28K | 4.7M | |
1.5M | -1.2M | 3.1M | 352.8K | 1.1M | 1.3M | 269.5K | |
-18.8M | -15.7M | -13.1M | -12.1M | -4.1M | -1.8M | -1.6M | |
INVESTING ACTIVITIES | |||||||
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (187.6K) | |
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (187.6K) | |
FINANCING ACTIVITIES | |||||||
18.5M | 18.8M | 11.4M | 14M | 5.7M | 50K | 2.1M | |
0.0 | 0.0 | 0.0 | 0.0 | 7.4M | 668.9K | 10K | |
-617.1K | -578.1K | -2.1M | -1.5M | 860.4K | 79.2K | 125K | |
17.9M | 18.2M | 9.3M | 12.5M | 14M | 798.1K | 2.2M | |
CASH FLOW SUMMARY | |||||||
-5.2K | -21.5K | -117.0 | -4.4K | 0.0 | 0.0 | 864.8K | |
-943.3K | 2.5M | -3.8M | 376.6K | 9.9M | -1M | 1.7M | |
9.6M | 7.2M | 11M | 10.6M | 663.5K | 1.7M | 0.0 | |
8.7M | 9.6M | 7.2M | 11M | 10.6M | 663.5K | 1.7M | |
-18.8M | -15.7M | -13.1M | -12.1M | -4.1M | -1.8M | -1.6M |
SEC Filings
MAIA - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | May 22, 2026 | May 21, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 14, 2026 | May 14, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 11, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 16, 2026 | April 16, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 08, 2026 | April 08, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 07, 2026 | May 21, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 02, 2026 | March 27, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 31, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 27, 2026 | March 27, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 23, 2026 | December 31, 2025 | 2025 |
Related Guides
Continue your MAIA research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.